INS and diabetic ketoacidosis: In addition, there was a decrease in prandial insulin dose (weighted mean difference of −4.23 IU; 95% CI = −5.26 to −3.20), basal insulin dose (−2.40 IU; −3.93 to −0.87), and total insulin dose (−5.73 IU; −10.61 to −0.86).32 Importantly, these benefits were not associated with a risk of severe hypoglycemia, diabetic ketoacidosis (DKA), or severe adverse events but were associated with higher rates of GI adverse events.32